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42ABSTRACT
Background. Long cold ischemia time (CIT) is the most important factor contributing to
delayed graft function (DGF) after kidney transplant. Improvements in pretransplant
procedures may reduce CIT and improve clinical outcome.
Materials and Methods. Pretransplant histocompatibility tests were modernized at our
laboratory in 2015, leading to signiﬁcant decrease of time consumed for these enabling
earlier surgery. The effects of this on kidney transplant CIT, DGF, and other clinical
outcomes were studied. The study population consisted of 896 consecutive deceased donor
kidney recipients, of which 442 patients received a transplant with the old crossmatch and
454 received a transplant with the new crossmatch.
Results. CIT shortened from mean 20 hours 6 minutes to 15 hours 52 minutes (P < .001).
The incidence of DGF was signiﬁcantly reduced from 31% to 24% (P ¼ .02). Reduction in
the frequency of DGF was more pronounced among the highly sensitized patients (53% to
28%, P ¼ .01) or in patients with pretransplant donor-speciﬁc antibodies (50% to 20%, P ¼
.002) and among patients who received kidneys from donors older than 65 years (38% to
27%, P ¼ .04).
Conclusions. Process optimization that reduces CIT decreases occurrence of DGF,
especially in highly sensitized patients and patients who receive kidneys from older donors.INCREASED cold ischemia time (CIT) is the mostimportant factor contributing to delayed graft function
(DGF) after kidney transplant [1], and continuous efforts
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COLD ISCHEMIA AND DELAYED GRAFT FUNCTION 43replace the need for prospective cytotoxic crossmatching, it
still remains the gold standard in successful kidney trans-
plant, especially in sensitized patients [2e4].
Originally spleen or lymph nodes of deceased donors
were used to yield sufﬁcient number of both B and T cells
to perform a reliable cytotoxic crossmatch, but with the
more speciﬁc techniques to purify T and B cell pop-
ulations, peripheral blood is now widely used as a source.
This enables prospective crossmatching to be started even
before the deceased donor organ retrieval operation and
thus may reduce CIT signiﬁcantly, as has been shown by
others [5].
Our institution serves as the only transplant center for a
nationwide relatively large geographic area, with long
distances for patients to travel to the transplant operation.
With an unacceptably high frequency of DGF after
deceased donor kidney transplant reaching almost 40% in
our institution [6], an initiative was launched to optimize
CIT to reduce the occurrence of DGF. The aim of this
study was to assess the possibility of improving clinical
outcomes with enhancing the cooperation between the
transplant center and histocompatibility laboratory and to
ﬁnd possible subgroups that would beneﬁt the most from
reductions in cold ischemia time.MATERIALS AND METHODS
Donors and Patients
All donors and patients were categorized into group 1 (transplant
performed before October 12, 2015, a time of introduction of new
crossmatching method) or group 2 (after October 12, 2015). Our
institution is the only transplantation center in Finland and is also
responsible for all of the organ procurement operations. According to
Scandiatransplant exchange rules (http://www.scandiatransplant.org/
organ-allocation/guidelines), some of the deceased donor organs are
transplanted in other countries within the Scandiatransplant area. All
donors were brain dead because donors after circulatory death are
currently not used inFinland.Machineperfusionwas not used in any of
the transplants.
All deceased donor kidney transplant recipients in our center who
received transplants during a 2-year period before and after the his-
tocompatibility testing changes, that is, patients between October 9,
2013, andOctober16, 2017 (N¼ 896),were included in thisprospective
follow-up study of an inception cohort. All patients were either on
hemodialysis or peritoneal dialysis before transplant, and no pre-
emptive deceased donor kidney transplants were performed during
the study period. Altogether 442 patients received a transplant in the
selected era of the old crossmatch (group 1), and 454 received a
transplant with the new crossmatch (group 2). Eighty-three trans-
planted kidneys were from donors of other Scandinavian countries: 43
and 40 in groups 1 and 2, respectively. Data about patient character-
istics, CIT, the occurrence of DGF, and possible rejection episodes
were gathered from theNational Transplant Registry, to which follow-
up data from transplant patients are prospectively collected, as obliged
by law.DGFwas deﬁned as the need for post-transplant dialysis during
theﬁrst week after transplant. Data about pretransplant donor-speciﬁc
HLAantibodies (DSAs) were collected fromFinnishRedCrossBlood
Service’s laboratory records.Donor-Recipient Matching Protocol, Cytotoxic
Crossmatching, and HLA Typing
Recipients for deceased donor kidney transplant were selected
based on a predesigned protocol taking into account ABO
compatibility and HLA-A, -B, and -DRB1 match, with emphasis on
DRB1 matching, waiting time, clinical evaluation, and negative
cytotoxic crossmatch.
On October 12, 2015, the method using density gradient-puriﬁed
spleen cells for crossmatching was replaced with puriﬁcation of
peripheral blood T and B cells for crossmatching using RosetteSep
kits (Stemcell Technologies, Vancouver, Canada), performed ac-
cording to manufacturers’ instructions. Internal validation of the
use of RosetteSep-separated peripheral T and B cells for cross-
match showed no relevant differences compared with splenocyte
crossmatch in the speciﬁcity and sensitivity (89% and 82%,
respectively). When the crossmatching methods were compared
with the cumulative (the sum of all individual DSAs above 1000
mean ﬂuorescence intensity [MFI]) DSAs of more than 3000 MFI
as standard, speciﬁcity and sensitivity were similar (81% and 67% in
peripheral T and B cell method, and 81% and 71% in splenocyte
method, respectively). Splenocyte crossmatch was performed using
the 2 latest patient sera (1 mL, 5 mL, and 1 mL 1/10 dilution with
2 mL standard rabbit complement and 1 mL with 4 mL complement).
The incubation times of the serum and cells were 20 minutes, after
complement 60 minutes, and with color 20 minutes. Dithiothreitol
treatment was used if IgM antibodies were previously detected. All
cases having more visually detected dead cells compared with
negative control were called positive. Peripheral T and B cell
crossmatches were performed similarly, but in B cells the cutoff for
positive level was increased to more than 20% of dead cells. Also,
complement incubation period was reduced to 30 minutes.
Spleen retrieval was performed simultaneously with transplant-
able organs, but peripheral blood samples were usually delivered to
the laboratory before donor operation. Patient sera used for initial
crossmatches were collected previously for HLA antibody analyses
and stored at the laboratory.
HLA-A, -B, and -DRB1 loci of the patients were determined
with Luminex using One Lambda LABType kits (One Lambda Inc,
Canoga Park, Calif, Untied States). Before June 2015, the donor
HLA typing for HLA-A, -B, -C, -DRB1, and -DQB1 was performed
with sequence-speciﬁc primers (One Lambda Inc) and with
complement-mediated lymphocytotoxicity test (Biotest, Rockaway,
NJ, United States).
After introduction of LINKSEQ qualitative polymerase chain
reaction method with HLA-ABCDRDQA1DQB1DP 384 Typing
Kit (Linkage Biosciences, San Francisco, Calif, United States) in
June 2015, HLA-DPA1, -DPB1, -DQA1, and -DRB3-5 have also
been determined at low resolution level. High-resolution results
have been recorded whenever possible either because of adequate
typing resolution or based on well-known haplotypes. HLA typing
was performed according to donor center rules in 83 cases with
exchanged kidney, and at least HLA-A, -B, -C, -DRB1, and -DQB1
loci were determined at low-resolution level in all donors.
Time spent for HLA typing including splenocyte (group 1) or T
and B cell (group 2) crossmatches for possible thoracic organ or
pancreas transplant recipients, time spent during waiting for the
kidney transplant candidate list for the crossmatches from the
transplantation ofﬁce, and time spent for kidney transplant cross-
matches with splenocytes in group 1 and with T and B cells in group
2 were gathered from all local donor cases with adequate laboratory
records in 2014 (group 1, N ¼ 101) and 2016 (group 2, N ¼ 104).
This sample approach was selected to ensure that all personnel
Table 1. Time Spent (min) for Different Steps During
Histocompatibility Tests in 2 Selected Time Periods: 2014
(Group 1) and 2016 (Group 2)
Group 1
(N ¼ 101)
Group 2
(N ¼ 104) P Value
Start HLA typed*
Mean (SD) 277 (58) 229 (62) < .001‡
Median (range) 265 (165-450) 210 (120-410)
List waiting
Mean (SD) 100 (74) 107 (83) .6
Median (range) 85 (15-435) 88 (5-435)
Crossmatches†
Mean (SD) 531 (200) 204 (59) < .001‡
Median (range) 490 (235-1155) 190 (125-590)
Laboratory work time
Mean (SD) 807 (213) 430 (87) < .001‡
Median (range) 765 (500-1500) 410 (305-780)
Total time
Mean (SD) 907 (221) 536 (120) < .001‡
Median (range) 870 (520-1615) 515 (345-1015)
*Includes locally performed HLA typing and crossmatches for thoracic organ
and pancreas transplant recipients.
†Includes crossmatches for kidney transplant recipients.
‡P <.05.
44 LAURONEN, PERÄSAARI, SAARINEN ET ALworking on-call duties were familiar with the old and new methods.
Mean total time consumed for histocompatibility testing decreased
from 15 hours 7 minutes to 8 hours 56 minutes (P < .001). Effects of
methodologic changes to time spend for histocompatibility test are
shown in detail in Table 1.
DSA Analyses
One Lambda Labscreen mixed- and single-antigen beads with
Luminex were used for HLA antibody screening and identiﬁcation
with the use of HLA Fusion software (One Lambda Inc). A
normalized MFI cutoff point of 1000 was used for positivity in single
antigen analyses. Donor speciﬁcity of all positive antibodies were
evaluated, and MFI values of detected DSAs were recorded, with
the exception of HLA-DP antibodies of those cases where donor
HLA-DP type was unknown (n ¼ 12 and n ¼ 4 in groups 1 and 2,
respectively).Table 2. Donor and Pat
Group
Donor age, mean (SD), y 5
Patient age at time of transplant, mean (SD), y 5
Patient sex, % female
Retransplant, %
Class I HLA mismatch, mean, No.
Class II HLA mismatch, mean, No.
Pretransplant peritoneal dialysis, No. (%) 16
Tacrolimus based immunosuppression, No. (%) 17
Induction immunosuppression, No. (%) 7
ATG 3
Basiliximab 4
Sensitized pretransplant (%)
Highly sensitized (PRA > 80%) pretransplant (%)
Pretransplant DSA (%)
Abbreviations: ATG, antithymocyte globulin; DSA, donor-speciﬁc HLA antibody; P
*P < .05.Immunosuppression
Immunosuppression was a combination of cyclosporine or tacro-
limus, mycophenolate, and steroids. Induction was not used in the
majority of the patients, but induction with basiliximab or
antithymocyte globulin (ATG) was given to patients with higher
immunologic risk, such as patients with poor HLA match,
increased level of panel-reactive antibodies (PRAs), or known
pretransplant DSAs with clinician’s discretion. Virtual crossmatch
results were usually not available at the time of transplant, and in
addition to induction therapy, no desensitization was used peri-
operatively for patients with DSAs. Trough level targets for
cyclosporine and tacrolimus were similar for all patients regard-
less of the induction used, and no differences were made to the
policies during the study period. Immunosuppression protocol has
been previously reported in detail [7].Statistics
Continuous variables were compared using the Mann-Whitney U
test. Categorical variables were compared using the c2 test. Sur-
vival was analyzed with the Kaplan-Meier method, and differ-
ences between the groups were analyzed with the log-rank test.
The independent impact of CIT on the risk of DGF was analyzed
with multivariable binary logistic regression analysis, with the
occurrence of DGF as the binary outcome. All covariates with
P < .1 in univariable analysis were selected to the ﬁnal multi-
variable model. SPSS version 21 (IBM, Armonk, NY, United
States) was used for analysis. P values < .05 were considered
statistically signiﬁcant.Ethical Aspects
This study was based purely on registry data and was approved by
the scientiﬁc committee of the Finnish Red Cross Blood Service
and by the Hospital District for Helsinki and Uusimaa (HUS/269/
2017). The coordinating ethical committee for the Hospital District
of Helsinki and Uusimaa has also approved the use of patient
record data for scientiﬁc studies (42/13/03/00/11). The persons
involved in this study were treated in a manner in accordance with
both the Declaration of Helsinki and the Declaration of Istanbul.ient Characteristics
1 (N ¼ 442) Group 2 (N ¼ 454) P Value
6 (16) 55 (16) .92
2 (15) 53 (15) .13
37 33 .19
16 14 .53
2 2 .84
1 1 .92
1 (36) 138 (30) .30
7 (40) 226 (50) .03*
3 (17) 121 (27) < .001*
3 (7) 61 (13)
0 (9) 60 (13)
42 35 .02*
12 13 .36
10 12 .18
RA, panel-reactive antibody.
Table 3. Clinical End Points Among Patients Who Received
Transplants During the Old Crossmatch (Group 1) or the New
Crossmatch (Group 2)
Group 1
(N ¼ 442)
Group 2
(N ¼ 454)
P
Value
Cold ischemia time,
mean (SD), h
20 (4) 16 (6) < .001*
Nonfunction, No. (%) 8 (1.8) 8 (1.8) > .99
DGF, No. (%) 139 (31) 111 (24) .02*
Dialysis sessions needed
post Tx in patients with DGF,
mean (SD), No.
5 (4) 4 (4) .23
Acute cellular rejection, No. (%) 48 (11) 57 (13) .47
Acute humoral rejection, No. (%) 22 (5) 15 (3) .24
Plasma creatinine at the end
of follow-up, mean
(SD), mmol/L
147 (125) 150 (91) .72
1-year graft survival, No. (%) 414 (94) 432 (95) .39
1-year patient survival, No. (%) 421 (95) 440 (97) .23
Abbreviations: post Tx, post transplant; DGF, delayed graft function.
*P < .05.
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Patients
Patients included in the study are described in Table 2.
Patients in group 1 were more frequently sensitized before
transplant (P ¼ .02), but the frequency of highly sensitized
patients (PRA > 80%) or patients with pretransplant
DSAs did not differ between the groups. Patients in group
2 received more frequently tacrolimus-based immuno-
suppression and induction therapy with ATG or basilix-
imab, but no other signiﬁcant differences were found in
the baseline characteristics between the patients in groups
1 or 2. At the end of follow-up on December 31, 2017, a
total of 845 grafts (94%) were functioning, and 866
patients (96%) were alive.0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Group 1 Group 2Clinical End Points
Table 3 compares the clinical end points between patients in
groups 1 and 2. CIT reduced from mean 20 hours 8 minutes
(SD, 4 hours 36 minutes) in group 1 to 15 hours 50 minutes
(SD, 5 hours 12 minutes) in group 2 (P < .001). Figure 1
shows the distribution of CIT in the 2 groups. Among pa-
tients in group 1, only 17% of patients received transplants
within 16 hours of CIT compared with 53% in group 2.
Altogether 16 patients (8 patients in each group) expe-
rienced early graft loss during the ﬁrst week after transplant
owing to vascular thrombosis without graft function or pri-
mary nonfunction of unknown cause. No cases of hyper-
acute rejection were observed. The frequency of DGF was
139 of 442 (31%) in group 1 compared with 111 of 454
(24%) in group 2 (P ¼ .02). No signiﬁcant differences were
seen in the number of dialysis sessions needed among pa-
tients with DGF. No differences were seen in the frequency
of biopsy-proven acute cellular or humoral rejections or in
graft function at the end of follow-up. Similarly, no differ-
ences were seen in graft or patient survival between the
groups.
Sensitivity Analyses
Sensitized patients. When only patients with known DSAs
at the time of transplant were included in the analyses, the
reduction in the frequency of DGF was even more pro-
nounced: 22 of 44 (50%) in group 1 compared with 11 of 55
(20%) (P ¼ .002). A similar effect was seen when only
highly sensitized patients (pretransplant PRA > 80%) were
included because the frequency of DGF was reduced from
28 of 52 (53%) in group 1 to 17 of 59 (28%) (P ¼ .01). The
reduction in CIT was similar in patients with DSAs at the
time of transplant or highly sensitized patients, from mean
20 hours in group 1 to mean 14 hours or 15 hours in group 2,
respectively. To avoid possible bias in the severity of> 24 h
20-24 h
16-20 h
12-16 h
< 12 h
Fig 1. Distribution of cold
ischemia times before (group 1)
and after (group 2) the change of
the laboratory procedures.
Table 4. Characteristics of the Patients With Donor-Speciﬁc
Antibodies
Patients with DSAs
Group 1
(N ¼ 44 of
442, 10%)
Group 2
(N ¼ 56 of
454, 12%)
P
Value
No. of DSAs, No. (%) .66
1 24 (55) 27 (48)
2 8 (18) 15 (27)
3 7 (16) 9 (16)
 4 5 (11) 5 (9)
DSAs against, No. (%) .42
Class I 28 (64) 30 (54)
Class II 9 (20) 12 (21)
Both 7 (16) 14 (25)
Cumulative MFI,
median (range)
4986
(1061-31190)
8208
(1001-54363)
.24
Patients on tacrolimus
(vs cyclosporine),
No. (%)
33 (75) 43 (78) .81
Patients receiving
induction, No. (%)
.06
Basiliximab 12 (27) 15 (27)
ATG 4 (9) 15 (27)
Cold ischemia time,
mean (SD), h
20 (4) 14 (4) < .001
Patients with acute
rejection, No. (%)
9 (20) 17 (30) .26
Abbreviations: ATG, antithymocyte globulin; DSA, donor-speciﬁc antibody;
MFI, mean ﬂuorescence intensity.
46 LAURONEN, PERÄSAARI, SAARINEN ET ALsensitization between the groups, both the highly sensitized
group (PRA > 80%) and patients with pretransplant DSAs
are compared in Tables 4 and 5. No signiﬁcant differences
were recorded between the groups regarding number of
DSAs, the distribution of DSAs between HLA class I and
II antibodies, median cumulative MFI, the frequency of
acute rejection, or the immunosuppression used. A
statistically nonsigniﬁcant trend was seen toward more use
of ATG in patients with pretransplant DSAs in the group
2, whereas the cumulative median MFI of the DSAs was
slightly higher in group 2.
Impact of donor age. When only patients who received a
kidney from a donor 65 years or older were included, the
frequency of DGF was 50 of 130 (38%) in group 1 and 43
of 160 (27%) in group 2 (P ¼ .04). The reduction in CIT
was similar in patients who received kidneys from donors
65 years or older compared with younger donors, from
mean 21 hours in group 1 to mean 17 hours in group 2,
respectively (P < .001). On the contrary, when patients
received a kidney from a donor younger than 45 years, no
signiﬁcant difference was seen in the frequency of DGF: 16
of 78 (21%) in group 1 and 17 of 110 (15%) in group 2
(P ¼ .4). Among patients who received a graft from a
donor younger than 45 years with a CIT less than 12 hours,
only 3 of 54 (6%) developed DGF. On the other hand,
among the 290 patients who received a kidney from a
donor 65 years or older, only 21 patients received trans-
plants with a CIT of less than 12 hours, and only 1 of them
(5%) developed DGF.Multivariable Model of Risk Factors for DGF
A binary logistic regression model was built to analyze the
independent effect of cold ischemia on DGF. Covariates
with P < .1 in univariable analysis were selected to the ﬁnal
multivariable model shown in Table 6. Odds ratio for CIT
(per 1 hour increase) in univariable model was 1.12 (95%
CI, 1.09-1.16, P < .001). When CIT was categorized to 5
categories (< 12h, 12-15.9 h, 16-19.9 h, 20-23.9 h, and > 24
h), each incremental increase in CIT was associated with an
increased risk for DGF (odds ratio, 1.62; 95% CI, 1.42-1.84;
P < .001). Increased CIT remained an independently sig-
niﬁcant risk factor in the adjusted model, with an odds ratio
of 1.11 for each 1-hour increase in CIT. No signiﬁcant ﬁrst-
degree interactions were seen between CIT and the other
variables. In addition to the variables included in the
multivariable model shown in Table 6, variables such as the
use of tacrolimus (vs cyclosporine), HLA mismatch, or
recipient or donor sex were tested but were not associated
with the risk of DGF in univariable analyses.
DISCUSSION
In this study, we were able to show that CIT can be reduced
by optimizing histocompatibility testing, leading to reduced
incidence of DGF. In addition, because other treatment
policies remained unchanged during the study period, we
had a possibility to examine the independent impact of CIT
on the risk of DGF.
In addition to CIT, which is regarded as the most
important risk factor for DGF [1], other factors contribute
to the risk of DGF after deceased donor kidney transplant,
such as donor age [8], presence of DSA [9], pretransplant
hemodialysis [6], management of the brain-dead donor
[10,11], and possible use of machine perfusion during the
cold storage [12]. The extent of ischemia-reperfusion injury
to the graft causing DGF is likely a multifactorial process in
which the weight of the individual components is not
entirely discovered because many of the factors are inter-
related. For example, highly sensitized patients may have
their kidney shipped from other centers and may need
conﬁrmatory prospective crossmatching, resulting in
increased CIT. Our study provides important insights to the
actual contribution of CIT to the risk of DGF. In our
analysis, donor age was an important risk factor for DGF,
and among patients with a young donor and short CIT (< 12
h), the frequency of DGF was very low, only 6%. On the
other hand, we were able to show that reducing CIT might
be even more important among kidneys transplanted from
older donors because the reduction in the occurrence of
DGF was more pronounced among donors 65 years or
older. Other studies have reported similar ﬁndings of the
increased susceptibility to cold storage of kidneys from older
donors [13e15].
Another subgroup of patients who seemed to achieve
more beneﬁt from reduction of CIT were highly sensitized
patients because we found that the reduction in the fre-
quency of DGF was substantial among highly sensitized
Table 5. Characteristics of the Highly Sensitized Patients
Highly Sensitized Patients (PRA > 80%) Group 1 (N ¼ 53 of 442, 12%) Group 2 (N ¼ 59 of 454, 13%) P Value
Patients with DSA, No. 26 33 .57
No. of DSAs, No. (%) .97
1 8 (15) 10 (17)
2 7 (13) 10 (17)
3 6 (11) 8 (14)
 4 5 (9) 5 (8)
DSAs against, No. (%) .64
Class I 17 (32) 19 (32)
Class II 5 (9) 7 (12)
Both 3 (6) 7 (12)
Cumulative MFI, median (range) 8825 (1114-31190) 12992 (1001-53362) .11
Patients on tacrolimus (vs cyclosporine), No. (%) 43 (81) 49 (83) .81
Patients receiving induction, No. (%) .29
Basiliximab 13 (25) 20 (34)
ATG 7 (13) 11 (19)
Cold ischemia time, mean (SD), h 20 (4) 15 (4) < .001
Patients with acute rejection 11 (21) 14 (24) .82
Abbreviations: ATG, antithymocyte globulin; DSA, donor-speciﬁc antibody; MFI, mean ﬂuorescence intensity; PRA, panel-reactive antibody.
COLD ISCHEMIA AND DELAYED GRAFT FUNCTION 47patients or patients with DSAs at the time of transplant,
from 52% to 28% and 50% to 20%, respectively. We have
previously demonstrated that the presence of pretransplant
DSAs increases the risk of DGF after kidney transplant [9].
The increased immunogenicity in the graft caused by
ischemia-reperfusion injury [16] might be even more detri-
mental among patients with already baseline higher risk for
immunologic events. In our current analysis, pretransplant
DSA was not an independent risk factor for DGF, which
might be explained by different deﬁnitions of DGF in our
previous study and the fact that the use of induction
immunosuppression has been increasing in our institution
since the previous study. In fact, patients in group 2 were
more likely to receive induction immunosuppression, which
might be a confounding factor when assessing the risk of
DGF. Selection of the induction treatment was based on
clinician’s discretion to choose between basiliximab and
ATG. Induction immunosuppression, however, was not
independently associated with the risk of DGF in the cur-
rent study.
In their excellent report, Aubert et al have shown that the
presence of DSAs and long CIT are both detrimental to
extended criteria donor kidney transplant survival [17]. OurTable 6. Multivariable Model of the Impact of the Cold Ischem
Univariable Model
OR 95% CI
Cold ischemia time, h 1.12 1.08-1.16
Donor age, y 1.02 1.01-1.03
Retransplant 1.19 1.31-2.81
Highly sensitized status 1.90 1.26-2.86
Recipient female sex 0.72 0.53-0.97
Induction therapy 0.56 0.38-0.83
Pretransplant peritoneal dialysis 0.33 0.21-0.50
Abbreviation: OR, odds ratio.results of the beneﬁcial effect of CIT reduction especially in
patients with DSAs or kidney transplant from an older
donor are in line with those ﬁndings. However, our end
point was DGF, not graft of patient survival, and our results
do not necessarily mean that our patients with a higher
frequency of DGF may also have poorer outcome in the
long run or that reduced CIT in these subgroups actually
may enhance graft of patient survival. In fact, no difference
in short-term graft or patient survival, graft function in the
long term, or the frequency of acute rejection could be
detected between the groups in our current study, suggest-
ing that the reduced frequency of DGF may not translate to
long-term beneﬁt of the transplant. Conﬂicting data exist in
the literature about the association of DGF with long-term
outcomes, and not all data support the harmful long-term
effects of DGF [15,18].
Similar ﬁndings of logistical factors inﬂuencing CIT have
been reported by others [3e5,19]. In a prospective multi-
center study from the United Kingdom, Shrestra et al
showed that the use of donor peripheral blood for cross-
matching was associated with reduced CIT. Frequencies of
DGF, however, were not included in this report. The
shortest CITs were reported in patients with transplantsia Time for Delayed Graft Function After Kidney Transplant
Multivariable Model
P Value OR 95% CI
P
Value
< .001 1.11 1.07-1.15 < .001
< .001 1.02 1.01-1.03 .004
.001 1.52 0.94-2.46 .09
.002 1.88 1.14-3.10 .01
.03 0.69 0.51-0.95 .02
.004 0.69 0.43-1.10 .12
< .001 0.38 0.24-0.60 < .001
48 LAURONEN, PERÄSAARI, SAARINEN ET ALperformed with virtual crossmatching and no prospective
cytotoxic crossmatching [5]. A major limitation to this policy
is that virtual crossmatching is usually only suitable for
nonsensitized patients or patients with only limited sensiti-
zation and low number of unacceptable HLA antigens. One-
third of our population in the current study were sensitized
pretransplant and not optimally suitable for virtual cross-
matching, and these patients are at the highest risk of
increasing CIT and DGF.
Our decision to use potentially less sensitive peripheral
blood leukocytes for cytotoxic crossmatch could lead to
increased rate of false negative results when the presence of
DSAs is used as the deﬁnition of true positive. It is known
that especially low MFI level Luminex-based HLA-antibody
ﬁndings are clinically too sensitive [20e22]. However, oc-
casionally high-level DSAs are also seen in crossmatch
negative patients. We have accepted this since these pa-
tients usually have prolonged waiting time, are highly
sensitized, and have a very limited chance of ﬁnding virtual
crossmatch negative transplants. Flow cytometric cross-
match could improve the accuracy of crossmatching. How-
ever, previous studies from our laboratory and our
experience has shown that ﬂow cytometric crossmatch cor-
relates rather well with virtual crossmatch [23]. Therefore,
adding ﬂow cytometric crossmatch to our protocol might
only add another layer of studies but might not be cost
effective or clinically helpful. Naturally, we aim to add virtual
crossmatch to our protocol as an additional decision-making
tool for clinicians. Despite less sensitive biological cross-
match methods, no hyperacute rejection episodes of kidney
transplants have been detected at our clinic after negative
cytotoxic crossmatch, neither in the previous era with sple-
nocyte crossmatching nor in the current era of peripheral
blood leukocyte crossmatching. The concept of using periph-
eral blood cells for crossmatching is not new and has been
successfully adopted by several centers. Thus, our ﬁndings
regarding the crossmatching policy are not novel, and reduc-
tion in CIT and the frequency of DGF could be expected.
However, the purpose of this study was more to demonstrate
that changes in policies and cooperation between the trans-
plant center and histocompatibility laboratory can lead to
meaningful improvement in clinical outcomes.
Our study has some limitations of note. Because this was
a single-center study, the ﬁndings might not be applicable to
other kidney transplant populations. In addition, although
treatment policies in our center have remained stable since
October 2013, the use of tacrolimus and induction therapy
have increased in the latter patient group, and we cannot
rule out unidentiﬁed confounding factors. Only limited data
were available regarding the deceased donors, and some
variables associated with the risk of DGF (such as donor
body mass index, cause of death, or data on management of
the deceased donor) could not be adjusted for, limiting our
analyses. However, no changes occurred in donor accep-
tance or management policies during the study period, and
likely no differences exist between the study groups
regarding the management or selection of the brain-deaddonors. On the other hand, our study includes a relatively
large number of kidney transplants from deceased donors
within a short time-period, allowing us to analyze the in-
dependent impact of CIT on the risk of DGF.CONCLUSIONS
Enhanced histocompatibility testing methods can help to
reduce CIT and the occurrence of DGF in kidney trans-
plantation, showing that major improvements in patient
care and results of kidney transplant can be made by opti-
mizing the crosstalk between the histocompatibility testing
laboratory and the transplantation center. Highly sensitized
patients and patients who receive kidney from older donors
seem to beneﬁt more from the reduction in CIT.REFERENCES
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